Multiscale Bioimaging (MBExC) -2067- is a Cluster of Excellence of the University of Göttingen, Germany and is funded by the German Federal Government and the Länder (federal states) since 2019.
Research at the MBExC is aimed at the heart and the brain as disorders of these organs are major causes of disability and death. The electrically excitable cells of these widely distinct organs, cardiomyocytes and neurons, have surprisingly many physiological properties in common. The goal of the MBExC is to decipher disease relevant nanoscale functional units in the heart and the brain by using a multiscale approach that integrates research on nanoscale units with analyses of excitable cell networks by using state-of-the-art bioimaging techniques. Together with an interdisciplinary research network across the Göttingen Campus, we provide unique insights into both cardiac and neural networks and develop innovative therapeutic strategies for disorders affecting the heart, the brain, or both.
Hertha Sponer College
Multiscale integrative research performed by MBExC scientists offers unique opportunities for the interdisciplinary training of early career researchers coming from a basic science or medical background. The Hertha Sponer College targets particularly talented students and early career researchers interested in further personalized research training and career advice to spark and foster enthusiasm for research at the boundary of the natural sciences and biomedicine. The overall aim is to promote cutting-edge, interdisciplinary early career researchers on their way to independence, to thus educate a new generation of future research leaders.
The US-American National Academy of Sciences has elected Patrick Cramer as Foreign Associate. The prestigious academy thus honors the biochemist for his outstanding research on
When we hear, the sensory hair cells in the cochlea of the inner ear transduce sound signals of a certain pitch and convert them for
A milestone in hearing research: Researchers at the University Medical Center Göttingen and the University of Freiburg combine for the first time gene therapy in